


REGISTERED NUMBER: 13045376 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD
26 NOVEMBER 2020 TO 30 NOVEMBER 2021
FOR
INSPIRA PHARMACEUTICALS LIMITED

These accounts replace the original accounts filed for this period on 10 November 2022. These accounts are now the statutory accounts for the company for the period 30 November 2021 and have been prepared as they were at the date of the original accounts.



**CONTENTS OF THE FINANCIAL STATEMENTS
for the Period 26 November 2020 to 30 November 2021**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

INSPIRA PHARMACEUTICALS LIMITED

COMPANY INFORMATION
for the Period 26 November 2020 to 30 November 2021

DIRECTORS:

N L Woolf
R J Mcgoldrick
J E Jackson

REGISTERED OFFICE:

27 Old Gloucester Street
London
WC1N 3AX

REGISTERED NUMBER:

13045376 (England and Wales)

ACCOUNTANTS:

Oury Clark Chartered Accountants
Herschel House
58 Herschel Street
Slough
Berkshire
SL1 1PG

BALANCE SHEET
30 November 2021

	Notes	£	£
FIXED ASSETS			
Intangible assets	4		112,842
CURRENT ASSETS			
Debtors	5	15,653	
Cash at bank		10,130	
		<u>25,783</u>	
CREDITORS			
Amounts falling due within one year	6	58,360	
		<u></u>	
NET CURRENT LIABILITIES			<u>(32,577)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>80,265</u>
CAPITAL AND RESERVES			
Called up share capital			46,470
Share premium			254,024
Retained earnings			<u>(220,229)</u>
			<u>80,265</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 November 2021.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 November 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 May 2023 and were signed on its behalf by:


R J McGoldrick - Director

The notes form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS
for the Period 26 November 2020 to 30 November 2021

1. STATUTORY INFORMATION

Inspira Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at costs less accumulated amortisation and any accumulated impairment losses.

Development costs are not currently being amortised as the asset under development is not available for use.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL.

4. INTANGIBLE FIXED ASSETS

	Other intangible assets £
COST	
Additions	112,842
At 30 November 2021	<u>112,842</u>
NET BOOK VALUE	
At 30 November 2021	<u><u>112,842</u></u>

INSPIRA PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 13045376)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 26 November 2020 to 30 November 2021

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Other debtors

£
15,653

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Trade creditors

£
58,360